MDACC Study No:2004-0190 ( NCT No: NCT00427765)
Title:A Phase II study of high-dose intravenous busulfan plus melphalan with allogeneic or autologous marrow or peripheral blood progenitor cell transplantation for lymphoid malignancies or multiple myeloma.
Principal Investigator:Partow Kebriaei
Treatment Agent:Busulfan; Melphalan
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if giving busulfan along
with melphalan, followed by allogeneic or autologous bone marrow (BMT) or
peripheral blood stem cell transplant (PBSCT) can safely help to control the
disease in patients with advanced hematologic cancer. The therapeutic component
of this study is the use of busulfan and melphalan, which are established
chemotherapy drugs for stem cell transplantation. The research aspect of this
protocol is the pharmacokinetic dosing and monitoring of Busulfan as explained
in the optional procedures section below.
Hide details for General InformationGeneral Information

Disease Group:Leukemia; Lymphoma; Myeloma
Phase of Study:Phase II
Treatment Agents:Busulfan
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:100 days post transplant, and will include inpatient and out patient care
during this time period.
Supported By:N/A
Return Visit:Every 3 months during the first year if possible.
Home Care:IV fluids, etc. as determined by patient's clinical status.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Partow Kebriaei
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-745-0663
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults